文献速递浆细胞疾病造血干细胞移植与细胞治疗

溶瘤免疫治疗与硼替佐米协同改善难治性多发性骨髓瘤生存

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
PubMed 文献 · Blood Adv · 2019-01-01

该临床前研究探讨溶瘤呼肠孤病毒(RV)与标准治疗药物硼替佐米(BTZ)联合治疗多发性骨髓瘤(MM)的协同作用。体外实验显示RV与BTZ在耐药人MM细胞系中具有协同作用;在BTZ耐药免疫健全同基因Vk*MYC移植小鼠模型中,RV/BTZ联合治疗降低肿瘤负荷并改善总生存(P < .00001)。作者认为RV/BTZ联合是治疗MM有吸引力的治疗策略且无安全性信号。

要点

  • RV与BTZ在耐药人MM细胞系体外实验中显示协同作用。
  • BTZ耐药Vk*MYC小鼠中RV/BTZ联合降低肿瘤负荷并改善总生存(P < .00001)。
  • BTZ增强RV在肿瘤相关内皮细胞和骨髓瘤细胞中的复制。

核心结论

  • 作者认为联合RV/BTZ是治疗MM有吸引力的治疗策略且无安全性信号。

研究设计与样本

  • 临床前研究:体外耐药人MM细胞系实验及同基因Vk*MYC BTZ耐药免疫健全可移植MM小鼠模型实验。

主要发现

  • RV与BTZ在耐药人MM细胞系体外实验中协同并增强其治疗潜力。
  • 在BTZ不敏感MM肿瘤小鼠中,RV/BTZ联合治疗降低肿瘤负荷并改善总生存(P < .00001)。
  • BTZ增强RV在肿瘤相关内皮细胞和骨髓瘤细胞中的复制,促进病毒递送并刺激细胞因子释放、免疫活性、凋亡及减少MM相关免疫抑制。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Thirukkumaran CM, Shi ZQ, Nuovo GJ, et al. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv. 2019. PMID: 30850386. doi:10.1182/bloodadvances.2018025593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。